News

The Spinal Muscular Atrophy (SMA) Biomarkers Study is the first trial within the NeuroNEXT Network to enroll a participant

NeuroNEXT Trial of SMA Biomarkers Enrolls First Participant

21/Dec/2012

The Spinal Muscular Atrophy (SMA) Biomarkers in the Immediate Postnatal Period of Development Study seeks to identify prognostic and surrogate biomarkers of disease progression that will facilitate the execution of therapeutic SMA clinical trials in infants.

In December 2012, the SMA study enrolled its first participant, the first of any Network for Excellence in Neuroscience Clinical Trials, NeuroNEXT, Trials.

See the announcement.

patient

U.S. News and World Report Best Hospitals 2012-2013

U.S. News & World Report ranks Mass General the #1 hospital in America based on our quality of care, patient safety and reputation in 16 different specialties. Learn more about why we're #1.

Search the Mass General news archive

Search the archive for previously published news articles, press releases and publications.

View all departments

Departments and Centers at Mass General have a reputation for excellence in patient care. View a list of all departments.

  • © 2013 Massachusetts General Hospital
  • 617-726-2000
  • TDD: 617-724-8800

Site Map

  • Partners Healthcare
  • Harvard Medical School
  • Massachusetts General Physicians Organization
  • MassGeneral Hospital for Children
  • Individual Care, Global Impact: The Campaign for the Third Century of MGH Medicine
  • Proto